Endocrine MPA enhances the effects of TAC chemotherapy on improvement of prognosis and increase in long-term survival rates for patients with endometrial cancer
| Autor: | Juan Xue, Jing Zhang, L I Li, L U Wang, Xiuhong Yuan |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Cancer Research
medicine.medical_specialty Chemotherapy Pathology business.industry Endometrial cancer medicine.medical_treatment Cancer Articles medicine.disease Gastroenterology Carboplatin Metastasis chemistry.chemical_compound Oncology chemistry Internal medicine Medicine Medroxyprogesterone acetate Endocrine system business Survival rate medicine.drug |
| Zdroj: | Oncology Letters. 10:1902-1906 |
| ISSN: | 1792-1082 1792-1074 |
| DOI: | 10.3892/ol.2015.3395 |
| Popis: | The aim of the present study was to investigate the effect of taxol, adriamycin and carboplatin (TAC) chemotherapy combined with endocrine medroxyprogesterone acetate (MPA) therapy for the treatment of patients with endometrial cancer. A retrospective analysis of 124 patients with endometrial cancer was performed by dividing the cohort into an experimental and control group. The 64 patients in the experimental group received TAC and MPA chemotherapy, whereas the 60 patients in the control group were treated with TAC chemotherapy only. Tissue samples scraped from the uterus were used to extract the total proteins and RNAs for the western blot and reverse transcription-quantitative polymerase chain reaction analyses, respectively. All the patients were followed up for 20–45 months, during which time prognostic data, and one- to three-year survival rates were recorded and compared. The rate of recurrence or metastasis was significantly lower in the experimental group compared with that in the control group (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|